Re­vamp com­ing at Gilead; Lat­est from in Ukraine, Rus­sia; Bio­gen’s hang­ing bud­get ax; No­var­tis places gene ther­a­py bet; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

Amid a big Omi­cron out­break here in Hong Kong, I re­cent­ly caught Covid-19 but thank­ful­ly on­ly had mild symp­toms and have al­ready re­cov­ered. Still, the ex­pe­ri­ence gave me even more ap­pre­ci­a­tion of rapid anti­gen tests and vac­cines — and the peo­ple in this in­dus­try be­hind those very re­al med­ical prod­ucts shap­ing our lives. Have a good week­end.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.